血清HBcrAg在慢性乙型肝炎患者中的表现，8年核苷（酸）类似

StephenW

Clin Res Hepatol Gastroenterol. 2018 Nov 26. pii: S2210-7401(18)30256-0. doi: 10.1016/j.clinre.2018.10.020. [Epub ahead of print]
Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.
Wang ML1, Deng R1, Chen EQ2, Tao CM3, Liao J1, Zhou TY1, Wang J1, Tang H4.
Author information

1
    Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China.
2
    Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China. Electronic address: [email protected].
3
    Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China.
4
    Center of infectious diseases, West China hospital, Sichuan university, Chengdu 610041, P.R. China; Department of laboratory medicine, West China hospital, Sichuan university, Chengdu 610041, P.R. China. Electronic address: [email protected].

Abstract
AIM:

This study aimed to investigate long-term kinetics of serum hepatitis B core-related antigen (HBcrAg) and its correlation with serum hepatitis B surface antigen (HBsAg) in a real-world cohort of patients who had received over 8 years of nucleos(t)ide analogs(NAs) therapy.
METHODS:

This was a retrospective study. All patients were recruited from our previous published study, who started therapy with NAs between 2007 and 2008. Serum HBcrAg and HBsAg levels were quantitatively measured at baseline, the sixth month and each year of follow-up, using the stored serum samples.
RESULTS:

Among the 94 patients, serum HBcrAg presented a gradually decreasing trend from baseline to year 8, either in HBeAg-negative or HBeAg-positive patients. After 8 years of NAs treatment, 21.3% of patients achieved serum HBcrAg < 3 log 10 U/mL, and only baseline HBcrAg was an independent predictor. Additionally, good correlation of HBcrAg and HBsAg was observed at baseline, but this correlation weakened remarkably during treatment.
CONCLUSION:

Serum HBcrAg is decreasing gradually with the duration of antiviral therapy, and baseline HBcrAg level is an independent predictor of long-term HBcrAg below the limit of detection.

Copyright © 2018 Elsevier Masson SAS. All rights reserved.
KEYWORDS:

Hepatitis B; Kinetics; Nucleos(t)ide analogs therapy; Serum hepatitis B core-related antigen

PMID:
    30497844
DOI:
    10.1016/j.clinre.2018.10.020

StephenW

Clin Res Hepatol Gastroenterol。 2018年11月26日.pii：S2210-7401（18）30256-0。 doi：10.1016 / j.clinre.2018.10.020。 [提前打印]
血清HBcrAg在慢性乙型肝炎患者中的表现，8年核苷（酸）类似物治疗。
Wang ML1，Deng R1，Chen EQ2，Tao CM3，Liao J1，Zhou TY1，Wang J1，Tang H4。
作者信息

1
    四川大学华西医院传染病研究中心，成都610041;四川大学华西医院实验医学系，成都610041，中国。
2
    四川大学华西医院传染病研究中心，成都610041;四川大学华西医院实验医学系，成都610041，中国。电子地址：[email protected]。
3
    四川大学华西医院实验医学系，成都610041，中国。
4
    四川大学华西医院传染病研究中心，成都610041;四川大学华西医院实验医学系，成都610041，中国。电子地址：[email protected]。

抽象
目标：

这项研究旨在调查血清乙型肝炎核心相关抗原（HBcrAg）的长期动力学及其与血清乙型肝炎表面抗原（HBsAg）的相关性，这些抗原是在接受过8年以上核的患者的实际队列中进行的。 ）ide类似物（NAs）疗法。
方法：

这是一项回顾性研究。所有患者均来自我们之前发表的研究，该研究于2007年至2008年间开始使用NA进行治疗。使用储存的血清样本，在基线，第6个月和每年随访时定量测量血清HBcrAg和HBsAg水平。
结果：

在94例患者中，血清HBcrAg从基线到第8年逐渐呈下降趋势，无论是HBeAg阴性还是HBeAg阳性患者。在NAs治疗8年后，21.3％的患者达到血清HBcrAg <3 log 10 U / mL，并且仅基线HBcrAg是独立的预测因子。此外，在基线时观察到HBcrAg和HBsAg的良好相关性，但这种相关性在治疗期间显着减弱。
结论：

随着抗病毒治疗的持续时间，血清HBcrAg逐渐下降，基线HBcrAg水平是低于检测限的长期HBcrAg的独立预测因子。

版权所有©2018 Elsevier Masson SAS。版权所有。
关键词：

乙型肝炎;动力学; Nucleos（t）ide类似物疗法;血清乙型肝炎核心相关抗原

结论：
    30497844
DOI：
    10.1016 / j.clinre.2018.10.020